MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from equity
issuance/offering-Securities Purchase...
$50,000K
Proceeds from equity
issuance/offering-At The Market...
$1,696K
Proceeds from exercise of
stock options
$26K
Maturities of marketable
securities
$54,650K
Net cash provided by
financing activities
$51,722K
Net cash provided by
investing activities
$17,378K
Canceled cashflow
$37,272K
Net increase in
cash, cash...
$30,590K
Canceled cashflow
$38,510K
Stock-based compensation
expense
$4,295K
Accounts payable
$2,383K
Depreciation and
amortization expense
$2,332K
Prepaid expenses, other
current assets and other...
-$90K
Other non-current
liabilities
$10K
Purchases of marketable
securities
$37,183K
Purchases of property and
equipment
$89K
Net cash used in
operating activities
-$38,510K
Canceled cashflow
$9,110K
Net loss
-$24,153K
Gain on securities
purchase agreement...
$17,561K
Accrued liabilities and
other current...
-$3,567K
Non-cash lease income
$1,100K
Net amortization
and accretion on...
$886K
Change in fair value of
success payment...
-$353K
Back
Back
Cash Flow
source: myfinsight.com
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)